Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Oxazolopyrimidines as Edg-1 receptor agonists

Oxazolopyrimidines as Edg-1 receptor agonists

US Patent 8735387 · Granted May 27, 2014

Estimated economic value: $7,978,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic ac2021
Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjug2020
Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic ac2020
Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists2020
Compounds as peptidic GLP1/glucagon/GIP receptor agonists2019
Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonist2018
Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obes2018
Substituted indanone compounds as GPR119 modulators for the treatment of diabete2018
Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists2017
{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-ace2017
{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-ace2017
Substituted fused heterocycles as GPR119 modulators for the treatment of diabete2017